

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
HIGHLY SPECIALISED TECHNOLOGY EVALUATION PROGRAMME**

Equality impact assessment – Scoping

HST Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations

Batch 56

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Because this is an autosomal recessive disease, it will be more prevalent in cultures in which it is more common to marry a family member (for example, first cousins).

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues

been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Sheela Upadhyaya

Date: 19/11/2018